GoldenGolden
Advanced Search
OrbiMed

OrbiMed

U.S-based venture capital and private equity firm investing on life sciences companies worldwide.

OrbiMed, also known as OrbiMed Advisors, is a private equity and venture capital firm established in 1989. The firm was founded by Carl L. Gordon and Sven H. Borho. Its headquarters is located in New York City, New York and it has additional offices in San Francisco, California; Mumbai, India; Shanghai, China; Herzliya, Israel and Hong Kong. As of March 2019, the firm is managing 152 companies in its current portfolio and has sold off its ownership in 205 companies. Its most recent investment was for Imara on March 2019, a company developing therapeutics for sickle cell disease treatment.

Funding

OrbiMed focuses on funding companies in the field of life sciences. The firm invests globally, with past investments on companies based in North America, Europe, and Asia (China, India, and Israel). The firm finances companies at various stages of development, from seed to buyouts. Its most recent funding round raised $551 million on September 2017.

Timeline

March 1, 2021
OrbiMed banks $3.5 billion in its latest raise, a sum that will be divided among three private investment funds, including one focused on early-stage companies in North America and Europe and a second aimed at companies of various stages in Asia.

People

Name
Role
LinkedIn

Carl Gordon

Managing Partner

Carter Neild

General Partner

Chau Knuong

Partner

David Wang

Partner

Geoffrey Hsu

General Partner

Jonathan Silverstein

Managing Partner

Jonathan Wang

Partner

Mathew Rizzo

Partner

Peter Thompson

Partner

Richard Klemm

Partner

Rishi Gupta

Partner

Scotland Stevens

General Partner

Scott Green

Partner

Sunny Sharma

Partner

Sven Borho

Managing Partner

Trevor Polischuk

Partner

William Sawyer

Partner

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Adaptimmune

Biopharmaceuticals

Adicet Bio

Biopharmaceuticals

Adimab

Biopharmaceuticals

Aeglea Biotherapeutics

Biopharmaceuticals

Aerpio

Biopharmaceuticals

Alector

Biopharmaceuticals

Alpine Immune Sciences

Biopharmaceuticals

Applied Immune Technologies

Biopharmaceuticals

Arrys Therapeutics

Biopharmaceuticals

Arsanis Biosciences

Biopharmaceuticals

Arvinas

Biopharmaceuticals

Ascendis Pharma

Atox Bio

Biopharmaceuticals

Attenua

Biopharmaceuticals

Audentes Therepeutics

Biopharmaceuticals

Avedro

Biopharmaceuticals

Avitide

Biopharmaceuticals

Baili Pharmaceutical

Biopharmaceuticals

Balance Therapeutics

Biopharmaceuticals

Bellus Health

Biopharmaceuticals

Bharat Serums and Vaccines

Biopharmaceuticals

BioLineRx

Biopharmaceuticals

CBT Pharmaceuticals

Biopharmaceuticals

ChemomAb

Biopharmaceuticals

Cleave Biosciences

Biopharmaceuticals

Page 1 of 5

News

Title
Author
Date
Publisher
Description
binx health, inc
May 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people...
Alex Keown
May 26, 2021
BioSpace
BioSpace looks at five of the top investor companies that support life sciences companies across the industry.
Ben Adams
May 12, 2021
FierceBiotech
OrbiMed's executive partner and a founder of rare disease biopharma Alexion (now AstraZeneca), Stephen Squinto, Ph.D., is taking the reins at non-viral gene therapy biotech Gennao Bio.
i2020 Accelerator
April 29, 2021
www.prnewswire.com:443
/PRNewswire/ -- i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, has announced multiple start-up and...
Annalee Armstrong
April 13, 2021
FierceBiotech
Theseus Pharmaceuticals, led by a team of ex-Ariad executives, will target treatment-resistant cancers after emerging from stealth mode with $100 million in Series B funding.
FinSMEs
April 13, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Theseus Pharmaceuticals
April 13, 2021
www.prnewswire.com:443
/PRNewswire/ -- Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase...
Amirah Al Idrus
March 1, 2021
FierceBiotech
OrbiMed banked $3.5 billion in its latest raise, a sum that will be divided among three private investment funds, including one focused on early-stage companies in North America and Europe and a second aimed at companies of various stages in Asia.
Yisheng Biopharma Co., Ltd.
February 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- YishengBio Co., Ltd. ("YishengBio", the "Company") announced today the closing of a US$130 million in Series B funding round. The new...
AnchorDx
February 23, 2021
www.prnewswire.com:443
/PRNewswire/ -- AnchorDx Medical Co., Ltd. ("AnchorDx") announced the completion of a USD 40 million Series C financing. This round of financing was jointly...
Conor Hale
January 13, 2021
FierceBiotech
A new method of screening the blood for the telltale signs of tumors promises to offer more chances for a successful result, and Delfi Diagnostics has raised $100 million to help make the cancer test a reality.
Enliven Therapeutics
December 7, 2020
www.prnewswire.com:443
/PRNewswire/ -- Enliven Therapeutics, a precision oncology company based in Boulder, CO, is announcing its launch from stealth with a bold mission: To help...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.